Voricosis, 200 mg 7 pcs
€1.00
Out of stock
(E-mail when Stock is available)
Voriconazole is a broad-spectrum antifungal agent of the triazole group. The mechanism of action is related to the inhibition of 14α-sterol demethylation mediated through fungal cytochrome P450; this reaction is a key step in ergosterol biosynthesis. Accumulation of 14α-methylsterol correlates with the subsequent loss of ergosterol in fungal cell membranes, which determines the antifungal activity of voriconazole.
Indications
- oesophageal candidiasis;
- severe fungal infections caused by Scedosporium spp. and Fusarium spp.
- other severe invasive fungal infections with intolerance or refractoriness to other medications;
- candidaemia in patients without neutropenia;
- severe invasive candidiasis infections (including Candida krusei);
- Prevention of invasive fungal infections in patients (adults and children over 12 years) in high-risk groups such as hematopoietic stem cell transplant recipients.
Active ingredient
Voriconazole
How to take, the dosage
The drug VORIKOZ (micronized) is administered orally, 1 hour before a meal or 1 hour after a meal. The tablet should be swallowed whole, without chewing, with plenty of water.
Electrolyte disorders such as hypokalemia, hypomagnesemia, and hypocalcemia should be corrected before therapy.
In adults the drug is given on the first day in the recommended saturation dose to achieve plasma concentration of voriconazole close to equilibrium concentration on the first day of therapy.
The indications | Patients with body weight ≥40 kg | Patients with body weight | |
Saturating dose all indications (first 24 hours) 6 mg/kg every 12 hours intravenous voriconazole for at least 7 days, after which switching to oral medication is possible, provided the patient is able to take oral medication. | |||
Maintenance doses (after the first 24 h) | |||
Prevention of invasive fungal infections in high-risk patients (adults and children over 12 years of age), such as hematopoietic stem cell transplant recipients. Prevent “breakthrough” fungal infections in febrile patients | 200 mg every 12 h | 100 mg every 12 h | |
Invasive aspergillosis, infections caused by Scedosporium spp. and Fusariumspp, other severe invasive fungal infections. | 200 mg every 12 h | 100 mg every 12 h | |
Candidaemia in patients without evidence of neutropenia | 200 mg every 12 h /p> | 100 mg every 12 h | |
Esophageal candidiasis | 200 mg every 12 h | 100 mg every 12 h |
Weight | 0.020 kg |
---|---|
Shelf life | 3 years. |
Conditions of storage | Store in a dry, light-protected place at 8 °C to 25 °C. |
Manufacturer | Hyglans Laboratories Pvt. Ltd, India |
Medication form | pills |
Brand | Hyglans Laboratories Pvt. Ltd |
Related products
Buy Voricosis, 200 mg 7 pcs with delivery to USA, UK, Europe and over 120 other countries.